CA2751712C - Immunotherapie et vaccins perfectionnes - Google Patents

Immunotherapie et vaccins perfectionnes Download PDF

Info

Publication number: CA2751712C
Authority: CA; Canada
Prior art keywords: protein; plasmid; cells; tnf; dna
Prior art date: 1996-10-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA2751712A

Other languages

English (en)

Other versions

CA2751712A1 (fr

Inventor

David B. Weiner

Jong J. Kim

Bin Wang

Jean D. Boyer

Velpandi Ayyavoo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Pennsylvania Penn

Original Assignee

University of Pennsylvania Penn

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-23

Filing date

1997-10-23

Publication date

2016-11-22

1997-10-23 Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn

1998-04-30 Publication of CA2751712A1 publication Critical patent/CA2751712A1/fr

2016-11-22 Application granted granted Critical

2016-11-22 Publication of CA2751712C publication Critical patent/CA2751712C/fr

2017-10-23 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 71
230000001976 improved effect Effects 0.000 title abstract description 18
238000009169 immunotherapy Methods 0.000 title description 4
108090000623 proteins and genes Proteins 0.000 claims abstract description 360
102000004169 proteins and genes Human genes 0.000 claims abstract description 294
108010065805 Interleukin-12 Proteins 0.000 claims abstract description 239
102000013462 Interleukin-12 Human genes 0.000 claims abstract description 221
239000000427 antigen Substances 0.000 claims abstract description 151
108091007433 antigens Proteins 0.000 claims abstract description 148
102000036639 antigens Human genes 0.000 claims abstract description 148
239000002773 nucleotide Substances 0.000 claims abstract description 127
125000003729 nucleotide group Chemical group 0.000 claims abstract description 127
230000001105 regulatory effect Effects 0.000 claims abstract description 103
230000003053 immunization Effects 0.000 claims abstract description 93
108090000174 Interleukin-10 Proteins 0.000 claims abstract description 71
102000003814 Interleukin-10 Human genes 0.000 claims abstract description 69
108010002350 Interleukin-2 Proteins 0.000 claims abstract description 68
102000000588 Interleukin-2 Human genes 0.000 claims abstract description 68
108090000172 Interleukin-15 Proteins 0.000 claims abstract description 65
102000003810 Interleukin-18 Human genes 0.000 claims abstract description 65
108090000171 Interleukin-18 Proteins 0.000 claims abstract description 64
108010002616 Interleukin-5 Proteins 0.000 claims abstract description 64
102000000743 Interleukin-5 Human genes 0.000 claims abstract description 64
102000003812 Interleukin-15 Human genes 0.000 claims abstract description 63
230000002519 immonomodulatory effect Effects 0.000 claims abstract description 62
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 54
108090000978 Interleukin-4 Proteins 0.000 claims abstract description 54
102000004388 Interleukin-4 Human genes 0.000 claims abstract description 54
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims abstract description 46
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
102000000589 Interleukin-1 Human genes 0.000 claims abstract description 15
108010002352 Interleukin-1 Proteins 0.000 claims abstract description 15
229940124551 recombinant vaccine Drugs 0.000 claims abstract description 14
239000013612 plasmid Substances 0.000 claims description 270
244000052769 pathogen Species 0.000 claims description 75
239000000203 mixture Substances 0.000 claims description 70
230000001717 pathogenic effect Effects 0.000 claims description 69
206010028980 Neoplasm Diseases 0.000 claims description 66
230000002163 immunogen Effects 0.000 claims description 64
201000011510 cancer Diseases 0.000 claims description 56
108091028043 Nucleic acid sequence Proteins 0.000 claims description 44
208000023275 Autoimmune disease Diseases 0.000 claims description 43
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 24
206010046865 Vaccinia virus infection Diseases 0.000 claims description 23
208000007089 vaccinia Diseases 0.000 claims description 23
108010008038 Synthetic Vaccines Proteins 0.000 claims description 13
230000002238 attenuated effect Effects 0.000 claims description 8
238000000034 method Methods 0.000 abstract description 93
150000007523 nucleic acids Chemical class 0.000 abstract description 80
108020004707 nucleic acids Proteins 0.000 abstract description 75
102000039446 nucleic acids Human genes 0.000 abstract description 75
-1 BL-1 Proteins 0.000 abstract description 37
108010041986 DNA Vaccines Proteins 0.000 abstract description 34
229940124590 live attenuated vaccine Drugs 0.000 abstract description 4
229940023012 live-attenuated vaccine Drugs 0.000 abstract description 4
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 184
235000018102 proteins Nutrition 0.000 description 177
229940117681 interleukin-12 Drugs 0.000 description 148
230000028993 immune response Effects 0.000 description 129
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 113
241000699670 Mus sp. Species 0.000 description 109
230000014509 gene expression Effects 0.000 description 102
108020004414 DNA Proteins 0.000 description 99
108090000695 Cytokines Proteins 0.000 description 95
108091026890 Coding region Proteins 0.000 description 87
102000004127 Cytokines Human genes 0.000 description 81
238000002649 immunization Methods 0.000 description 81
239000007924 injection Substances 0.000 description 80
238000002347 injection Methods 0.000 description 80
230000004044 response Effects 0.000 description 77
229940090044 injection Drugs 0.000 description 72
102100040247 Tumor necrosis factor Human genes 0.000 description 70
210000000952 spleen Anatomy 0.000 description 70
108060008682 Tumor Necrosis Factor Proteins 0.000 description 68
241000725303 Human immunodeficiency virus Species 0.000 description 57
239000012634 fragment Substances 0.000 description 57
230000002068 genetic effect Effects 0.000 description 57
239000013598 vector Substances 0.000 description 51
210000003527 eukaryotic cell Anatomy 0.000 description 44
238000011282 treatment Methods 0.000 description 41
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
230000000694 effects Effects 0.000 description 40
208000030507 AIDS Diseases 0.000 description 39
210000001744 T-lymphocyte Anatomy 0.000 description 38
201000010099 disease Diseases 0.000 description 37
241000701022 Cytomegalovirus Species 0.000 description 34
210000004698 lymphocyte Anatomy 0.000 description 34
230000008488 polyadenylation Effects 0.000 description 34
229940021995 DNA vaccine Drugs 0.000 description 32
239000013604 expression vector Substances 0.000 description 32
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 30
238000003556 assay Methods 0.000 description 29
230000000638 stimulation Effects 0.000 description 29
210000002443 helper t lymphocyte Anatomy 0.000 description 27
238000004519 manufacturing process Methods 0.000 description 27
239000003795 chemical substances by application Substances 0.000 description 26
230000009089 cytolysis Effects 0.000 description 25
230000003463 hyperproliferative effect Effects 0.000 description 25
238000002474 experimental method Methods 0.000 description 24
208000015181 infectious disease Diseases 0.000 description 24
238000011260 co-administration Methods 0.000 description 23
208000031886 HIV Infections Diseases 0.000 description 22
239000012636 effector Substances 0.000 description 22
208000037357 HIV infectious disease Diseases 0.000 description 20
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 20
230000006698 induction Effects 0.000 description 20
230000000770 proinflammatory effect Effects 0.000 description 20
108700005077 Viral Genes Proteins 0.000 description 19
230000001404 mediated effect Effects 0.000 description 19
108090000765 processed proteins & peptides Proteins 0.000 description 19
230000001939 inductive effect Effects 0.000 description 18
210000003719 b-lymphocyte Anatomy 0.000 description 17
230000004663 cell proliferation Effects 0.000 description 17
238000001727 in vivo Methods 0.000 description 17
125000003275 alpha amino acid group Chemical group 0.000 description 16
238000000338 in vitro Methods 0.000 description 16
125000005647 linker group Chemical group 0.000 description 16
230000035755 proliferation Effects 0.000 description 16
108091008874 T cell receptors Proteins 0.000 description 15
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 15
239000002299 complementary DNA Substances 0.000 description 15
125000000623 heterocyclic group Chemical group 0.000 description 15
230000008348 humoral response Effects 0.000 description 14
238000003259 recombinant expression Methods 0.000 description 14
241001465754 Metazoa Species 0.000 description 13
210000004988 splenocyte Anatomy 0.000 description 13
125000000008 (C1-C10) alkyl group Chemical group 0.000 description 12
238000002965 ELISA Methods 0.000 description 12
241000701806 Human papillomavirus Species 0.000 description 12
241000699666 Mus <mouse, genus> Species 0.000 description 12
230000024932 T cell mediated immunity Effects 0.000 description 12
241000700605 Viruses Species 0.000 description 12
230000005875 antibody response Effects 0.000 description 12
238000002255 vaccination Methods 0.000 description 12
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 11
230000000295 complement effect Effects 0.000 description 11
239000003937 drug carrier Substances 0.000 description 11
230000002708 enhancing effect Effects 0.000 description 11
230000006870 function Effects 0.000 description 11
102000046157 human CSF2 Human genes 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
239000007858 starting material Substances 0.000 description 10
101710205625 Capsid protein p24 Proteins 0.000 description 9
101710177166 Phosphoprotein Proteins 0.000 description 9
101710149279 Small delta antigen Proteins 0.000 description 9
206010041660 Splenomegaly Diseases 0.000 description 9
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 9
239000003814 drug Substances 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
230000001681 protective effect Effects 0.000 description 9
241000894006 Bacteria Species 0.000 description 8
206010009944 Colon cancer Diseases 0.000 description 8
206010020751 Hypersensitivity Diseases 0.000 description 8
239000002253 acid Substances 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
125000004122 cyclic group Chemical group 0.000 description 8
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 8
238000009472 formulation Methods 0.000 description 8
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
238000010561 standard procedure Methods 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
101710132601 Capsid protein Proteins 0.000 description 7
241000598436 Human T-cell lymphotropic virus Species 0.000 description 7
102000008070 Interferon-gamma Human genes 0.000 description 7
108010074328 Interferon-gamma Proteins 0.000 description 7
206010042971 T-cell lymphoma Diseases 0.000 description 7
150000007513 acids Chemical class 0.000 description 7
239000000872 buffer Substances 0.000 description 7
229960003150 bupivacaine Drugs 0.000 description 7
239000003085 diluting agent Substances 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
210000000987 immune system Anatomy 0.000 description 7
210000004072 lung Anatomy 0.000 description 7
210000003205 muscle Anatomy 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
230000009696 proliferative response Effects 0.000 description 7
230000011664 signaling Effects 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
230000002269 spontaneous effect Effects 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 6
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
208000003174 Brain Neoplasms Diseases 0.000 description 6
206010058467 Lung neoplasm malignant Diseases 0.000 description 6
206010037742 Rabies Diseases 0.000 description 6
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 6
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
125000003545 alkoxy group Chemical group 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
239000011651 chromium Substances 0.000 description 6
238000010367 cloning Methods 0.000 description 6
208000029742 colonic neoplasm Diseases 0.000 description 6
239000003623 enhancer Substances 0.000 description 6
230000028996 humoral immune response Effects 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
238000011081 inoculation Methods 0.000 description 6
201000005202 lung cancer Diseases 0.000 description 6
208000020816 lung neoplasm Diseases 0.000 description 6
210000002540 macrophage Anatomy 0.000 description 6
239000000047 product Substances 0.000 description 6
201000009410 rhabdomyosarcoma Diseases 0.000 description 6
206010039073 rheumatoid arthritis Diseases 0.000 description 6
239000000523 sample Substances 0.000 description 6
210000004989 spleen cell Anatomy 0.000 description 6
230000014616 translation Effects 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 5
108010062580 Concanavalin A Proteins 0.000 description 5
102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 5
101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 5
102000004083 Lymphotoxin-alpha Human genes 0.000 description 5
108090000542 Lymphotoxin-alpha Proteins 0.000 description 5
229920001213 Polysorbate 20 Polymers 0.000 description 5
230000006052 T cell proliferation Effects 0.000 description 5
208000030961 allergic reaction Diseases 0.000 description 5
229910052804 chromium Inorganic materials 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
230000009467 reduction Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
230000009261 transgenic effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 4
206010005003 Bladder cancer Diseases 0.000 description 4
206010005949 Bone cancer Diseases 0.000 description 4
208000018084 Bone neoplasm Diseases 0.000 description 4
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 4
101710091045 Envelope protein Proteins 0.000 description 4
108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 4
102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 4
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
108091006027 G proteins Proteins 0.000 description 4
102000030782 GTP binding Human genes 0.000 description 4
108091000058 GTP-Binding Proteins 0.000 description 4
241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
208000016604 Lyme disease Diseases 0.000 description 4
102000043129 MHC class I family Human genes 0.000 description 4
108091054437 MHC class I family Proteins 0.000 description 4
208000002231 Muscle Neoplasms Diseases 0.000 description 4
108700020796 Oncogene Proteins 0.000 description 4
208000009608 Papillomavirus Infections Diseases 0.000 description 4
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
101710188315 Protein X Proteins 0.000 description 4
102100036352 Protein disulfide-isomerase Human genes 0.000 description 4
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
239000013543 active substance Substances 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
230000003172 anti-dna Effects 0.000 description 4
229940031567 attenuated vaccine Drugs 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
238000001516 cell proliferation assay Methods 0.000 description 4
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000013461 design Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
230000036541 health Effects 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
239000002955 immunomodulating agent Substances 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
229960003130 interferon gamma Drugs 0.000 description 4
230000002147 killing effect Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
201000002077 muscle cancer Diseases 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
239000013641 positive control Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
238000011160 research Methods 0.000 description 4
210000003932 urinary bladder Anatomy 0.000 description 4
201000005112 urinary bladder cancer Diseases 0.000 description 4
208000003950 B-cell lymphoma Diseases 0.000 description 3
241000283707 Capra Species 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 3
102100020881 Interleukin-1 alpha Human genes 0.000 description 3
108010082786 Interleukin-1alpha Proteins 0.000 description 3
102000010789 Interleukin-2 Receptors Human genes 0.000 description 3
108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
108090001005 Interleukin-6 Proteins 0.000 description 3
102000004889 Interleukin-6 Human genes 0.000 description 3
108090001007 Interleukin-8 Proteins 0.000 description 3
102000004890 Interleukin-8 Human genes 0.000 description 3
241001529936 Murinae Species 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
241000714474 Rous sarcoma virus Species 0.000 description 3
206010039710 Scleroderma Diseases 0.000 description 3
239000013504 Triton X-100 Substances 0.000 description 3
229920004890 Triton X-100 Polymers 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000007815 allergy Effects 0.000 description 3
229940051881 anilide analgesics and antipyretics Drugs 0.000 description 3
150000003931 anilides Chemical class 0.000 description 3
230000008349 antigen-specific humoral response Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
230000007969 cellular immunity Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
210000003979 eosinophil Anatomy 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
238000007429 general method Methods 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000036039 immunity Effects 0.000 description 3
229940121354 immunomodulator Drugs 0.000 description 3
230000002584 immunomodulator Effects 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
230000010354 integration Effects 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000002609 medium Substances 0.000 description 3
229960002409 mepivacaine Drugs 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
230000002516 postimmunization Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
239000002510 pyrogen Substances 0.000 description 3
230000012121 regulation of immune response Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
101100519159 Arabidopsis thaliana PCR3 gene Proteins 0.000 description 2
208000004736 B-Cell Leukemia Diseases 0.000 description 2
241000589969 Borreliella burgdorferi Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
102100028372 COP9 signalosome complex subunit 6 Human genes 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
238000011238 DNA vaccination Methods 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
101710177291 Gag polyprotein Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000009465 Growth Factor Receptors Human genes 0.000 description 2
108010009202 Growth Factor Receptors Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
101000860047 Homo sapiens COP9 signalosome complex subunit 6 Proteins 0.000 description 2
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
102000003839 Human Proteins Human genes 0.000 description 2
108090000144 Human Proteins Proteins 0.000 description 2
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
108020005350 Initiator Codon Proteins 0.000 description 2
102100039898 Interleukin-18 Human genes 0.000 description 2
108090001090 Lectins Proteins 0.000 description 2
102000004856 Lectins Human genes 0.000 description 2
241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
101710125418 Major capsid protein Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
102000003505 Myosin Human genes 0.000 description 2
108060008487 Myosin Proteins 0.000 description 2
102000043276 Oncogene Human genes 0.000 description 2
108700006640 OspA Proteins 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
241000580858 Simian-Human immunodeficiency virus Species 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
241000589970 Spirochaetales Species 0.000 description 2
208000000389 T-cell leukemia Diseases 0.000 description 2
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
150000001558 benzoic acid derivatives Chemical class 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000011545 carbonate/bicarbonate buffer Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
229960002023 chloroprocaine Drugs 0.000 description 2
229960001747 cinchocaine Drugs 0.000 description 2
PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
201000010989 colorectal carcinoma Diseases 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
229960003624 creatine Drugs 0.000 description 2
239000006046 creatine Substances 0.000 description 2
230000007402 cytotoxic response Effects 0.000 description 2
125000005265 dialkylamine group Chemical group 0.000 description 2
208000037765 diseases and disorders Diseases 0.000 description 2
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000012645 endogenous antigen Substances 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
229940044627 gamma-interferon Drugs 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
230000036737 immune function Effects 0.000 description 2
230000001024 immunotherapeutic effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
230000003960 inflammatory cascade Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000003999 initiator Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000007914 intraventricular administration Methods 0.000 description 2
239000002523 lectin Substances 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000003589 local anesthetic agent Substances 0.000 description 2
229960005015 local anesthetics Drugs 0.000 description 2
238000002794 lymphocyte assay Methods 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
210000004216 mammary stem cell Anatomy 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
LJQWYEFHNLTPBZ-UHFFFAOYSA-N metabutoxycaine Chemical compound CCCCOC1=C(N)C=CC=C1C(=O)OCCN(CC)CC LJQWYEFHNLTPBZ-UHFFFAOYSA-N 0.000 description 2
229950004316 metabutoxycaine Drugs 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
229940035032 monophosphoryl lipid a Drugs 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
244000045947 parasite Species 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
230000004983 pleiotropic effect Effects 0.000 description 2
108700004029 pol Genes Proteins 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
229960004919 procaine Drugs 0.000 description 2
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
244000079416 protozoan pathogen Species 0.000 description 2
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
210000003314 quadriceps muscle Anatomy 0.000 description 2
108700042226 ras Genes Proteins 0.000 description 2
108700004030 rev Genes Proteins 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
229940031439 squalene Drugs 0.000 description 2
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
108700004027 tat Genes Proteins 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
229940126580 vector vaccine Drugs 0.000 description 2
108700026220 vif Genes Proteins 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
108700026215 vpr Genes Proteins 0.000 description 2
101150024249 vpr gene Proteins 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
ORVURRVCHHWGDK-UHFFFAOYSA-N 2-[[4-(3-chlorodiazirin-3-yl)benzoyl]amino]acetic acid Chemical compound C1=CC(C(=O)NCC(=O)O)=CC=C1C1(Cl)N=N1 ORVURRVCHHWGDK-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical class NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 1
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 description 1
SHSGDXCJYVZFTP-UHFFFAOYSA-N 4-ethoxybenzoic acid Chemical class CCOC1=CC=C(C(O)=O)C=C1 SHSGDXCJYVZFTP-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
206010003267 Arthritis reactive Diseases 0.000 description 1
206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000713826 Avian leukosis virus Species 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282465 Canis Species 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
MQIXMJWNEKUAOZ-KCFXOXMASA-N Cinnamoylcocaine Natural products O=C(O[C@H]1[C@H](C(=O)OC)[C@@H]2N(C)[C@H](C1)CC2)/C=C/c1ccccc1 MQIXMJWNEKUAOZ-KCFXOXMASA-N 0.000 description 1
NMPOSNRHZIWLLL-XUWVNRHRSA-N Cocaethylene Chemical group O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OCC)C(=O)C1=CC=CC=C1 NMPOSNRHZIWLLL-XUWVNRHRSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
102100031673 Corneodesmosin Human genes 0.000 description 1
101710139375 Corneodesmosin Proteins 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
241001466953 Echovirus Species 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
241000282324 Felis Species 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
241000710198 Foot-and-mouth disease virus Species 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
229940033347 HIV-1 DNA vaccine Drugs 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 1
101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
241001207270 Human enterovirus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102100039064 Interleukin-3 Human genes 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
241000186781 Listeria Species 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
241000282553 Macaca Species 0.000 description 1
210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 1
BXMFKNRZTLNAFY-UHFFFAOYSA-N Metabutethamine Chemical compound CC(C)CNCCOC(=O)C1=CC=CC(N)=C1 BXMFKNRZTLNAFY-UHFFFAOYSA-N 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
241001197446 Mus cypriacus Species 0.000 description 1
101000960949 Mus musculus Interleukin-18 Proteins 0.000 description 1
101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 description 1
KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
241000607768 Shigella Species 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
210000004241 Th2 cell Anatomy 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000001448 anilines Chemical class 0.000 description 1
235000020244 animal milk Nutrition 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
238000011394 anticancer treatment Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000001555 benzenes Chemical class 0.000 description 1
229960005274 benzocaine Drugs 0.000 description 1
VXJABHHJLXLNMP-UHFFFAOYSA-N benzoic acid [2-methyl-2-(propylamino)propyl] ester Chemical compound CCCNC(C)(C)COC(=O)C1=CC=CC=C1 VXJABHHJLXLNMP-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229940013767 bupivacaine injection Drugs 0.000 description 1
229960003369 butacaine Drugs 0.000 description 1
WDICTQVBXKADBP-UHFFFAOYSA-N butethamine Chemical compound CC(C)CNCCOC(=O)C1=CC=C(N)C=C1 WDICTQVBXKADBP-UHFFFAOYSA-N 0.000 description 1
229950009376 butethamine Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940105270 carbocaine Drugs 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000002230 centromere Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
201000003278 cryoglobulinemia Diseases 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000012137 double-staining Methods 0.000 description 1
239000006196 drop Substances 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
229960000385 dyclonine Drugs 0.000 description 1
BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
230000010502 episomal replication Effects 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
210000003013 erythroid precursor cell Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960003976 etidocaine Drugs 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010448 genetic screening Methods 0.000 description 1
208000001786 gonorrhea Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
102000052620 human IL10 Human genes 0.000 description 1
102000056003 human IL15 Human genes 0.000 description 1
102000043959 human IL18 Human genes 0.000 description 1
102000055229 human IL4 Human genes 0.000 description 1
102000055228 human IL5 Human genes 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229940124452 immunizing agent Drugs 0.000 description 1
239000000568 immunological adjuvant Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
YGSFZBYOMFZJPV-UHFFFAOYSA-N isobucaine Chemical compound CC(C)CNC(C)(C)COC(=O)C1=CC=CC=C1 YGSFZBYOMFZJPV-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
201000006512 mast cell neoplasm Diseases 0.000 description 1
208000006971 mastocytoma Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229950007594 meprylcaine Drugs 0.000 description 1
229960000774 metabutethamine Drugs 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
MQIXMJWNEKUAOZ-UYCDZTDFSA-N methyl (1s,3s,4r,5r)-8-methyl-3-[(e)-3-phenylprop-2-enoyl]oxy-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)\C=C\C1=CC=CC=C1 MQIXMJWNEKUAOZ-UYCDZTDFSA-N 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
230000035772 mutation Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
239000013642 negative control Substances 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229960003502 oxybuprocaine Drugs 0.000 description 1
CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
OWWVHQUOYSPNNE-UHFFFAOYSA-N parethoxycaine Chemical compound CCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1 OWWVHQUOYSPNNE-UHFFFAOYSA-N 0.000 description 1
229960003899 parethoxycaine Drugs 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
QXDAEKSDNVPFJG-UHFFFAOYSA-N phenacaine Chemical compound C1=CC(OCC)=CC=C1N\C(C)=N\C1=CC=C(OCC)C=C1 QXDAEKSDNVPFJG-UHFFFAOYSA-N 0.000 description 1
229950007049 phenacaine Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
XIMBESZRBTVIOD-UHFFFAOYSA-N piperidine-2-carboxamide Chemical compound NC(=O)C1CCCCN1 XIMBESZRBTVIOD-UHFFFAOYSA-N 0.000 description 1
229960001045 piperocaine Drugs 0.000 description 1
BMIJYAZXNZEMLI-UHFFFAOYSA-N piridocaine Chemical compound NC1=CC=CC=C1C(=O)OCCC1NCCCC1 BMIJYAZXNZEMLI-UHFFFAOYSA-N 0.000 description 1
229950001038 piridocaine Drugs 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
108010089520 pol Gene Products Proteins 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229960001896 pramocaine Drugs 0.000 description 1
DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
229960001807 prilocaine Drugs 0.000 description 1
MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
229960003981 proparacaine Drugs 0.000 description 1
229950003255 propoxycaine Drugs 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
229950010131 puromycin Drugs 0.000 description 1
229950000332 pyrrocaine Drugs 0.000 description 1
OYCGKECKIVYHTN-UHFFFAOYSA-N pyrrocaine Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCCC1 OYCGKECKIVYHTN-UHFFFAOYSA-N 0.000 description 1
150000004053 quinones Chemical class 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000012502 risk assessment Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
238000009738 saturating Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
229960004025 sodium salicylate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229940031626 subunit vaccine Drugs 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
210000003411 telomere Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960002372 tetracaine Drugs 0.000 description 1
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
229960004854 viral vaccine Drugs 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1
229960003434 xenysalate Drugs 0.000 description 1
HLDCSYXMVXILQC-UHFFFAOYSA-N xenysalate Chemical compound CCN(CC)CCOC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1O HLDCSYXMVXILQC-UHFFFAOYSA-N 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Zoology (AREA)
Mycology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Transplantation (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
AIDS & HIV (AREA)
Physics & Mathematics (AREA)
Tropical Medicine & Parasitology (AREA)
Plant Pathology (AREA)

CA2751712A 1996-10-23 1997-10-23 Immunotherapie et vaccins perfectionnes Expired - Lifetime CA2751712C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2861396P	1996-10-23	1996-10-23
US60/028613		1996-10-23
CA002269074A CA2269074A1 (fr)	1996-10-23	1997-10-23	Immunotherapie et vaccins perfectionnes

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002269074A Division CA2269074A1 (fr)	1996-10-23	1997-10-23	Immunotherapie et vaccins perfectionnes

Publications (2)

Publication Number	Publication Date
CA2751712A1 CA2751712A1 (fr)	1998-04-30
CA2751712C true CA2751712C (fr)	2016-11-22

Family

ID=21844431

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CA2751712A Expired - Lifetime CA2751712C (fr)	1996-10-23	1997-10-23	Immunotherapie et vaccins perfectionnes
CA2745736A Expired - Lifetime CA2745736C (fr)	1996-10-23	1997-10-23	Immunotherapie et vaccins perfectionnes
CA002269074A Abandoned CA2269074A1 (fr)	1996-10-23	1997-10-23	Immunotherapie et vaccins perfectionnes

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CA2745736A Expired - Lifetime CA2745736C (fr)	1996-10-23	1997-10-23	Immunotherapie et vaccins perfectionnes
CA002269074A Abandoned CA2269074A1 (fr)	1996-10-23	1997-10-23	Immunotherapie et vaccins perfectionnes

Country Status (8)

Country	Link
EP (1)	EP0958364A4 (fr)
JP (3)	JP2001507216A (fr)
KR (4)	KR20050053796A (fr)
CN (2)	CN1257976C (fr)
AU (1)	AU729579B2 (fr)
BR (1)	BR9712852A (fr)
CA (3)	CA2751712C (fr)
WO (1)	WO1998017799A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU752658B2 (en) *	1998-05-06	2002-09-26	Association Francaise Contre Les Myopathies	Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
AU2002301344B2 (en) *	1998-05-06	2005-01-13	Association Francais Contre Les Myopathies	Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
WO1999056775A1 (fr) *	1998-05-07	1999-11-11	Akzo Nobel N.V.	Emploi de l'interleukine 18 comme produit d'addition pour vaccin
US6316420B1 (en) *	1998-07-28	2001-11-13	Technion Research And Development Foundation Ltd.	DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
EP1168918A4 (fr) *	1999-03-03	2002-08-21	Univ Pennsylvania	Compositions vaccinales et de therapie genique, methodes de production et d'utilisations de celles-ci
HUP0200958A3 (en)	1999-04-23	2004-11-29	Pharmexa As	Method for down-regulating il5 activity
NZ515322A (en)	1999-05-13	2004-03-26	Wyeth Corp	Adjuvant combination formulations
US6943152B1 (en) *	1999-06-10	2005-09-13	Merial	DNA vaccine-PCV
CA2395840A1 (fr) *	1999-12-27	2001-07-05	The University Of Manitoba	Vaccins genetiques pour la production d'anticorps de jaune d'oeuf de poule diriges contre escherichia coli enterotoxinogene et d'autres pathogenes
US6544780B1 (en)	2000-06-02	2003-04-08	Genphar, Inc.	Adenovirus vector with multiple expression cassettes
US7754201B2 (en)	2000-06-02	2010-07-13	GenPhar, Inc	Method of vaccination through serotype rotation
US7092633B2 (en)	2000-11-14	2006-08-15	University Of Texas System Board Of Regents	System and method for configuring optical circuits
JP2002221520A (ja) *	2001-01-29	2002-08-09	Sumitomo Chem Co Ltd	免疫型の予測方法
CN1309836C (zh) *	2001-03-27	2007-04-11	萨斯喀彻温大学	培养环状病毒的方法
KR20030012199A (ko) *	2001-07-31	2003-02-12	(주)지노첵	사이토카인 유전자를 유효성분으로 포함하는 ｄｎａ 백신
WO2003059953A2 (fr)	2002-01-17	2003-07-24	Polymun Scientific Immunbiologische Forschung Gmbh	Anticorps anti-idiotypique induisant les anticorps neutralisant le vih-1
GB0223696D0 (en) *	2002-10-14	2002-11-20	Ml Lab Plc	Improved immunotherapy
MXPA05005051A (es)	2002-11-12	2006-03-10	Albert B Deisseroth	Vacuna de vector adenoviral.
EP1575601B1 (fr)	2002-12-16	2015-07-01	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Virus de la vaccine recombinants exprimant il-15 et méthodes d'utilisation des dits virus
US20040146486A1 (en) *	2003-01-24	2004-07-29	Juan Sun	Hybrid vector system for use as a vaccine
WO2004069272A2 (fr) *	2003-02-05	2004-08-19	Movecare Ltd	Combinaison d'adjuvants destinee a l'immunisation d'un mammifere et comprenant il et il12
NZ570709A (en) *	2003-06-13	2010-04-30	Univ Pennsylvania	Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US8299229B2 (en)	2003-11-24	2012-10-30	Microvax, Llc	Mucin antigen vaccine
US8828957B2 (en)	2003-12-11	2014-09-09	Microvax, Llc	Methods for generating immunity to antigen
KR101157694B1 (ko)	2003-12-17	2012-06-20	와이어쓰 엘엘씨	면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법
JP4696079B2 (ja)	2003-12-17	2011-06-08	ヤンセンアルツハイマーイミュノセラピー	Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
GB0410220D0 (en)	2004-05-07	2004-06-09	Kirkham Lea Ann	Mutant pneumolysin proteins
TW200613554A (en)	2004-06-17	2006-05-01	Wyeth Corp	Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CN101228272A (zh) *	2005-04-20	2008-07-23	生物载体株式会社	用于治疗阿尔茨海默病的具有较高安全性的经鼻腔内给药基因疫苗
EP3255141B1 (fr)	2006-07-13	2021-12-01	Wyeth LLC	Production de anticorps avec une gycosylation amelioree
ES2541546T3 (es)	2006-11-03	2015-07-21	Wyeth Llc	Sustancias que inhiben la glucólisis en cultivo celular
AU2008223133A1 (en)	2007-03-02	2008-09-12	Wyeth	Use of copper and glutamate in cell culture for production of polypeptides
KR101652767B1 (ko)	2008-04-04	2016-08-31	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	Ｉｌ-28을 이용한 백신 및 면역치료제, 및 그를 사용하는 방법 및 조성물
WO2010051820A1 (fr) *	2008-11-10	2010-05-14	Aarhus Universitet	Vaccination contre multiplexée par la cytokine
WO2010126766A1 (fr)	2009-04-30	2010-11-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Interleukine-12 inductible
US20130197612A1 (en) *	2010-02-26	2013-08-01	Jack W. Lasersohn	Electromagnetic Radiation Therapy
CN102370979B (zh) *	2011-10-10	2013-05-01	中国人民解放军第四军医大学	一种针对人TNF-α分子的自体疫苗的构建方法
HK1209140A1 (en)	2012-07-19	2016-03-24	Zoetis Services Llc	Bovine influenza c virus compositions
WO2014018724A1 (fr)	2012-07-27	2014-01-30	Zoetis Llc	Compositions de toxine de tique
EP2983703A1 (fr)	2013-03-15	2016-02-17	Zoetis Services LLC	Protection croisée de bovins contre une infection par b. trehalosi par un vaccin multivalent
KR20150130284A (ko) *	2013-03-15	2015-11-23	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	암 백신 및 이를 이용한 치료 방법
EP2970409A2 (fr)	2013-03-15	2016-01-20	Bioven 3 Limited	Protéines de synthèse à auto-assemblage
CA2995101A1 (fr)	2015-08-14	2017-02-23	Zoetis Services Llc	Compositions a base de mycoplasma bovis
WO2017123201A1 (fr)	2016-01-11	2017-07-20	Zoetis Services Llc	Nouvelles compositions vaccinales à protection croisée pour le virus de la diarrhée épidémique porcine
GB201703529D0 (en)	2017-03-06	2017-04-19	Cambridge Entpr Ltd	Vaccine composition
WO2018191619A1 (fr)	2017-04-13	2018-10-18	Senti Biosciences, Inc.	Immunothérapie anticancéreuse combinatoire
WO2019118760A1 (fr)	2017-12-13	2019-06-20	Inovio Pharmaceuticals, Inc.	Vaccins anti-cancéreux ciblant la mésothéline et leurs utilisations
KR102668476B1 (ko)	2017-12-13	2024-05-23	이노비오 파마수티컬즈, 인크.	Boris를 표적으로 하는 암 백신 및 이의 용도
WO2019118764A1 (fr)	2017-12-13	2019-06-20	Inovio Pharmaceuticals, Inc.	Vaccins anticancer ciblant muc16 et leurs utilisations
AU2019359890B2 (en)	2018-10-17	2024-10-24	Senti Biosciences, Inc.	Combinatorial cancer immunotherapy
US11419898B2 (en)	2018-10-17	2022-08-23	Senti Biosciences, Inc.	Combinatorial cancer immunotherapy
WO2020132595A1 (fr) *	2018-12-21	2020-06-25	The Regents Of The University Of California	Vaccins contenant de l'il-10 et leurs utilisations
CN110170049B (zh) *	2019-06-01	2023-07-04	山西农业大学	一种用于鸡球虫病活疫苗的细胞因子基因佐剂
CN119072330A (zh)	2022-03-14	2024-12-03	世代生物公司	异源初免加强疫苗组合物和使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0120906B1 (fr) *	1982-10-11	1988-09-21	National Research Development Corporation	Polypeptides utiles lors de vaccination contre des enterovirus
DE3751664T2 (de) *	1986-08-01	1996-06-05	Commw Scient Ind Res Org	Rekombinanter impfstoff
US5457038A (en) *	1988-11-10	1995-10-10	Genetics Institute, Inc.	Natural killer stimulatory factor
US5238823A (en) *	1990-08-22	1993-08-24	Veterinary Infectious Disease Organization	Interleukin-2-leukotoxin gene fusions and uses thereof
IL112820A0 (en) *	1994-03-07	1995-05-26	Merck & Co Inc	Coordinate in vivo gene expression
AU712714B2 (en) *	1994-10-03	1999-11-11	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system

1997
- 1997-10-23 AU AU50022/97A patent/AU729579B2/en not_active Expired
- 1997-10-23 CN CNB97180897XA patent/CN1257976C/zh not_active Expired - Lifetime
- 1997-10-23 EP EP97912961A patent/EP0958364A4/fr not_active Withdrawn
- 1997-10-23 KR KR1020057008602A patent/KR20050053796A/ko not_active Ceased
- 1997-10-23 KR KR1020047021499A patent/KR100629835B1/ko not_active Expired - Lifetime
- 1997-10-23 WO PCT/US1997/019502 patent/WO1998017799A1/fr not_active Ceased
- 1997-10-23 CA CA2751712A patent/CA2751712C/fr not_active Expired - Lifetime
- 1997-10-23 KR KR1020077024846A patent/KR20070108418A/ko not_active Ceased
- 1997-10-23 KR KR1019997003507A patent/KR100780158B1/ko not_active Expired - Lifetime
- 1997-10-23 CA CA2745736A patent/CA2745736C/fr not_active Expired - Lifetime
- 1997-10-23 CN CNA2006100718690A patent/CN1868545A/zh active Pending
- 1997-10-23 JP JP51971498A patent/JP2001507216A/ja not_active Ceased
- 1997-10-23 CA CA002269074A patent/CA2269074A1/fr not_active Abandoned
- 1997-10-23 BR BR9712852-0A patent/BR9712852A/pt not_active Application Discontinuation
2008
- 2008-02-27 JP JP2008045969A patent/JP2008194046A/ja active Pending
2009
- 2009-07-13 JP JP2009164572A patent/JP2009232860A/ja active Pending

Also Published As

Publication number	Publication date
CA2745736A1 (fr)	1998-04-30
JP2001507216A (ja)	2001-06-05
JP2008194046A (ja)	2008-08-28
CN1242045A (zh)	2000-01-19
CN1257976C (zh)	2006-05-31
BR9712852A (pt)	1999-11-16
CA2269074A1 (fr)	1998-04-30
WO1998017799A1 (fr)	1998-04-30
CA2745736C (fr)	2016-11-22
EP0958364A1 (fr)	1999-11-24
KR100629835B1 (ko)	2006-09-29
KR100780158B1 (ko)	2007-11-27
KR20070108418A (ko)	2007-11-09
EP0958364A4 (fr)	2001-10-31
KR20050053796A (ko)	2005-06-08
AU729579B2 (en)	2001-02-01
JP2009232860A (ja)	2009-10-15
KR20050008860A (ko)	2005-01-21
CN1868545A (zh)	2006-11-29
CA2751712A1 (fr)	1998-04-30
KR20000052710A (ko)	2000-08-25
AU5002297A (en)	1998-05-15

Legal Events

Date	Code	Title	Description
2011-08-22	EEER	Examination request
2017-12-25	MKEX	Expiry	Effective date: 20171023

Publication	Publication Date	Title
CA2751712C (fr)	2016-11-22	Immunotherapie et vaccins perfectionnes
WO1998017799A9 (fr)	1998-08-06	Immunotherapie et vaccins perfectionnes
US8202847B2 (en)	2012-06-19	Mutant human CD80 and compositions for and methods of making and using the same
EP0934083B1 (fr)	2009-04-29	Vaccins perfectionnes
IL138075A (en)	2012-08-30	Plasmids containing sequences of nucleic acids encoding immunogen and immunomodulatory protein, pharmaceutical preparations containing them and the use of such plasmids for the manufacture of drugs
AU774265B2 (en)	2004-06-24	Vaccines and gene therapy compositions and methods of making and using the same
US20040223974A1 (en)	2004-11-11	Vaccines, immunotherapeutics and methods for using the same
AU2001261590B2 (en)	2006-10-12	Vaccines, immunotherapeutics and methods for using the same
WO1999064074A1 (fr)	1999-12-16	Methodes et compositions permettant d'apporter des proteines a des cellules macrophages et a des cellules de lignee derivee de macrophages
AU2001261590A1 (en)	2002-02-14	Vaccines, immunotherapeutics and methods for using the same